Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cardlytics

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022

Cardlytics's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Cardlytics (NASDAQ:CDLX) posted Q1 earnings of $33.04 million, an increase from Q4 of 379.16%. Sales dropped to $67.93 million, a 24.57% decrease between quarters.

Cardlytics: Q1 Earnings Insights

Cardlytics (NASDAQ:CDLX) reported its Q1 earnings results on Monday, May 2, 2022 at 05:00 PM. Here's what investors need to know about the announcement. Earnings Cardlytics beat estimated earnings by 30.91%, reporting an EPS of $-0.38 versus an estimate of $-0.55.

Earnings Outlook For Cardlytics

Cardlytics (NASDAQ:CDLX) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Cardlytics will report an earnings per share (EPS) of $-0.55.

inkl

Read news from The Economist, FT, and more,
with one subscription

Cardlytics's Return On Capital Employed Overview

Cardlytics's Return On Capital Employed Overview

According to Benzinga Pro data, during Q4, Cardlytics (NASDAQ:CDLX) posted sales of $90.05 million. Earnings were up 73.42%, but Cardlytics still reported an overall loss of $11.84 million.

Analysts Remain Bullish On Cardlytics Post Q4 Results

Analysts Remain Bullish On Cardlytics Post Q4 Results

Analysts reiterated a Buy on Cardlytics Inc (NASDAQ:CDLX) post Q4 results. Craig-Hallum analyst Jason Kreyer lowered the firm's price target on Cardlytics from $100 to $70 (15% upside) and kept a Buy. The analyst notes quarterly results were strong despite lingering concerns over the supply chain, labor shortages, and omicron issues faced in the quarter. …

Recap: Cardlytics Q4 Earnings

Recap: Cardlytics Q4 Earnings

Cardlytics (NASDAQ:CDLX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Cardlytics beat estimated earnings by 64.29%, reporting an EPS of $-0.15 versus an estimate of $-0.42.

1

Organisations

Southwest Airlines

American Express

Advanced Micro Devices

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play